An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach. Consequently, the World Health Organization (WHO) has set the goal of eliminating hepatitis B and C by 2030. Dr Nicole Seguy (Regional Advisor HIV, hepatitis and STIs, WHO/Europe) summarizes the existing landscape of hepatitis B and C in a global context and discusses the interventions and advances that will help to achieve this goal.
‘Hepatitis B and C: Elimination as a Public Health Goal’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- Could you give us a brief overview of the global health burden of hepatitis B and C? (00:14)
- What elimination goals have been set by the WHO? (00:41)
- What interventions in terms of prevention and testing can help meet this goal? (01:18)
- What therapeutic advances have helped make elimination feasible? (02:08)
- What barriers exist to meeting this goal and how may they be overcome? (02:52)
Disclosures: Nicole Seguy has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
Share this Video
Related Videos In Hepatitis
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Marina Klein, AIDS2022: Triple elimination of HIV, HCV and HBV
Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss triple elimination of three infections (HIV, HBV and HCV) prevalent in low- and middle-income countries. Dr Klein highlights the challenges of transmission of HIV, hepatitis B and hepatitis C. She also looks current therapies for HIV, the elimination of Hepatitis C, […]
Anchalee Avihingsanon, AIDS2022: Bictegravir/FTC/TAF vs dolutegravir in HIV/HBV coinfected adults – ALLIANCE study interim results
The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!